Thomas Waldmann, M.D. is Chief Emeritus of the Lymphoid Malignancies Branch and is head of the Cytokine Immunology and Immunotherapy Section within NCI. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. He defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered. He also defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated the discovery with a trial of a Jak inhibitor in patients with this disorder. Dr. Waldmann was a NAI Fellow in 2017.